Details for Patent: 10,730,873

Which drugs does patent 10,730,873 protect, and when does it expire?

Patent 10,730,873 protects VENCLEXTA and is included in one NDA.

This patent has thirty-two patent family members in twenty-six countries.

Summary for Patent: 10,730,873

Title:	Salts and crystalline forms of an apoptosis-inducing agent
Abstract:	Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
Inventor(s):	Nathaniel Catron, Shuang Chen, Yuchuan Gong, Geoff G. Zhang
Assignee:	AbbVie Inc
Application Number:	US15/806,964
Patent Claim Types: see list of patent claims	Composition; Compound; Process;

Drugs Protected by US Patent 10,730,873

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	VENCLEXTA	venetoclax	TABLET;ORAL	208573-001	Apr 11, 2016	AB	RX	Yes	No	10,730,873			Y
Abbvie	VENCLEXTA	venetoclax	TABLET;ORAL	208573-002	Apr 11, 2016	AB	RX	Yes	No	10,730,873			Y
Abbvie	VENCLEXTA	venetoclax	TABLET;ORAL	208573-003	Apr 11, 2016	AB	RX	Yes	Yes	10,730,873			Y

International Family Members for US Patent 10,730,873

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2011332043
Brazil	112013012740
Canada	2817629
China	103328474
China	107266435
Cyprus	1119648